This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Disis, M. L. Articles by Hellström, I. Search for Related Content PubMed PubMed Citation Articles by Disis, M. L. Articles by Hellström, I.

¹ Tumor Vaccine Group, Division of Oncology, University of Washington and ² Laboratory of Tumor Immunology, Pacific Northwest Research Institute, Seattle, WA

Requests for Reprints: Mary L. Disis, Tumor Vaccine Group, Division of Oncology, Box 356527, University of Washington, Seattle, WA 98195-6527. Phone: (206) 616-1823; Fax: (206) 685-3128. E-mail: ndisis{at}u.washington.edu

DNA vaccines are ideally suited for immunizing against tumor antigens because constructs can be formulated that not only encode the tumor antigen but also encode molecules chosen to improve the ability to elicit an antitumor response. Ligands expressed on antigen-presenting cells associated with stimulating a robust T-cell response are excellent candidates for inclusion in a DNA vaccine. Mice transgenic for the HER-2/neu homologue, rat neu, were immunized with full-length rat neu cDNA given alone or in combination with plasmids encoding costimulatory molecules CD80 or CD86 and the ligand for CD137 (CD137L). Intradermal injection of the plasmid constructs resulted in both plasmid transcript and antigen protein expression being detected in lymph nodes draining the injection site. Immunization with plasmids encoding the neu antigen along with plasmids encoding CD137L and either CD80 or CD86 resulted in the generation of neu-specific antibodies that induced phopshorylation of the neu tyrosine kinase and inhibited the growth of cultured tumor cells overexpressing neu. Survival of animals was significantly prolonged after immunization with vaccines encoding neu together with the costimulatory molecules. Although tumors eventually occurred in the vaccinated animals, they were markedly infiltrated with CD4+ T cells. DNA vaccines encoding neu, when given in combination with both CD137L and either CD80 or CD86, can induce cellular and humoral immunity and result in an antitumor effect.

Note: M.L.D. and N.S. contributed equally to this manuscript.

Grant support: NIH SPORE grants CA98008 and CA85780. National Cancer Institute grant K24 CA85218 (M.L.D.). Department of Defense Breast Cancer Program fellowship (K.L.K.).

Received 3/25/03; revised 6/19/03; accepted 7/21/03.

This article has been cited by other articles:

				H. Zhang, K. L. Knutson, K. E. Hellstrom, M. L. Disis, and I. Hellstrom Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion Mol. Cancer Ther., January 1, 2006; 5(1): 149 - 155. [Abstract] [Full Text] [PDF]